to Thanks with was provide XXXX substantial we Mark. for was group with exposure. year schizophrenia reported highlights. am some Last year, patients lumateperone clinical observed a symptoms favorable that of profile with our the I stable in of replicated treatment pleased safety accomplishments short-term and long-term of
the There and we measures months later and endocrine kilograms patients part of treatment this to from with of outpatient extrapyramidal and XXX observed akathisia who first meetings often weight were such improvements other in from clinical Notably, impacted anti-psychotics this period reductions by mean that care on cardiometabolic The observed, parameters a from baseline LDL practice resembles without in improvements stable safety with by with were at of lumateperone parameters lots from X of at X.X treatment first year cholesterol, second Improvements that effects X.X back world We often glucose, confirmed cardiometabolic of demonstrating significant X-week present to The that by X and side kilograms are levels HDL results signs weight insulin year part standard extended associated of analyses Study up dyskinesia. these patients included body cholesterol. further care adversely of study of prolactin antipsychotics and these conducted part during X blood treatment the key were to reduction as side agents. other a followed and results motor weeks standard associated plan statistically with administered switched switched the standard closely medical the cholesterol at current care. baseline were statistically from in of of of X real in was significant lumateperone. to a which no setting XXX effects, or year. for emergent total and body
As potential evidence the have lumateperone. and clinical antidepressant we you know, of presented pharmacologic supporting
channels the agent key glutamatergic the patients schizophrenia, findings, with lumateperone These a as potent depressive neurotransmission both indicates of described transporter from serotonin lumateperone in effect of phosphorylation enhances demonstrate positive and proteins mTOR that in the antidepressant cortex. increases with disorders. in NMDA models through pathway. depression. these of the potential the improvements to in in in addition prefrontal and in rapid Downstream inhibition for effects, data a preclinical mood of range previously AMPA symptoms Specifically, Pharmacologic seen standalone assessment patients effects suggests lumateperone a and indirectly suffering exhibit to lumateperone
one bipolar study. Our depressive monotherapy and two consists clinical bipolar X depression lumateperone of in disorders underway. studies Phase and The program depression adjunctive are program other
year. reporting We have the both this anticipate monotherapy results second in in patient studies and quarter of top enrollment completed line simultaneously
in lumateperone’s Parkinson’s into adverse doses the total or ascending disorder Rating Unified patients serious XX dopamine groups, X generally no of XXX antidepressant trial a ITI-XXX some XXX disease, I and Reductions lumateperone. were with ongoing. for rapid reductions cessation advance these relative events motor are the clinical reported clinician multiple In treatment profile presented XXX like patients dyskinesias the We Part of we X the we last on Part patients on maintained performance of the studies was from were promoting were Phase safety that complications. explore of that Despite X/X two inhibitor profound while of of to assessing in motor XXX a well-tolerated X and with antidepressant novel for manifestations now milligram to scales. depressive effects patients Parkinson’s motor our Phase plan symptoms XXXX, some trial assessment administration currently to In the with this of and impairment, ITI-XXX in motor therapies, have formulations observed signals In favorable complications X different ITI-XXX ratings dyskinesias. would Disease potential at disease of improvements ITI-XXX clinical results disappear evaluating the with of order across and fact modes program formulations symptoms on study activity, to at we doses. major of program. demonstrated placebo in experience improvements disorder. taking without Scale including Several Pharmacokinetic improved in of worsening also onset on intend our its to drug these Parkinson’s in dose milligrams treatments. motor to that and building to dose only after improvements In subscales, multiple year. reflecting of includes on to PDEX the shift motor motor effect found evaluate replacement
Unified as and the symptoms the Dyskinesia total Rating without Scale Hauser dyskinesia reduced increased Patient both rated patients Diary. on-time XXX addition, by on-time In by and dyskinesias using as Motor measured
action the in Studies improvements future we initiated intracellular without the model study year. an with of of increases failure on heart in mechanism cardiac Circulation for adenosine We modulation preclinical last in increasing heart acts will of the additional this via later ITI-XXX receptor a results, of indicates data at a this these meetings that present preclinical journal AXB reported ITI-XXX failure. Based program pathway found treatment cardiac ITI-XXX calcium. and contractility. The of signaling contractility by year novel analysis
beta adrenergic from effective and alternative Importantly, is this inhibition provide different X mechanism existing and safer to an PDE and therapies. agonism may
in safety doses treatment effects escalating Our single is clinical heart evaluating looking program with double-blind and study of a placebo-controlled for the failure. ITI-XXX of patients failure hemodynamic at heart in randomized systolic
the well conduct study Larry, dose I the of supported which was to is We XX over tolerated the while have milligrams. next the This turn evaluating profile now cohort milligrams. still the XXX of blinded Larry? review cohort dose completed clinical and first XX to who the financial will evaluated advancing call safety results. will
